TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...

TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...

TriLink BioTechnologies, a Maravai LifeSciences company (MRVI), has partnered with, Avantor (AVTR) to expand availability of its innovative ...

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

KBR announced today its participation in upcoming February 2025 investor conferences. TD Cowen 46th Annual Aerospace and ...

MIAMI, Feb. 3, 2025 /PRNewswire-PRWeb/ -- kluster.ai, the decentralized AI platform, became the first to market to host DeepSeek-R1. The model matches OpenAI's performance in logic, mathematics, and ...

The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies. “Molecular Assemblies is the ...

Maravai LifeSciences (MRVI) announced its acquisition of intellectual property and relevant assets from Molecular Assemblies, or MAI. The ...

This acquisition is set to enhance the capabilities of Maravai's subsidiary, TriLink BioTechnologies, particularly in the field of mRNA and CRISPR nucleic acid-based therapies manufacturing.

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...